| PAVM:PAVmed Inc * | | Charting | News | Options |
*Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements |
||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
4.62% $0.09
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference |
|
| PR Newswire |
|
Lucid Diagnostics Inc.(Nasdaq: LUCD)("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that Lucid's President & Chief Operating Officer Shaun O'Neil will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 11:00 a.m. E.T. |
| Full Story → |
|
| Headline News |
|
| PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results |
| 7:33p ET March 26 '24 PR Newswire |
|
|
| Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard(R) Esophageal Precancer Testing in a Screening Population |
| 9:30a ET March 21 '24 PR Newswire |
|
|
| PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX |
| 8:30a ET March 21 '24 PR Newswire |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| April 19 '24. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, April 18 '24. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
